<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036188</url>
  </required_header>
  <id_info>
    <org_study_id>06715</org_study_id>
    <nct_id>NCT04036188</nct_id>
  </id_info>
  <brief_title>Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis</brief_title>
  <official_title>Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wright State Physicians</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wright State Physicians</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone
      cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis.
      The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4
      weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At
      that time, the study will become open-label and all subjects will be placed on (or continue)
      vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects, investigators and blinded research staff will be masked until subjects start the open label part of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Psoriasis Area and Severity Score (PASI) from baseline</measure>
    <time_frame>Week 28</time_frame>
    <description>Subjects achieving a 50% improvement from baseline (PASI 50)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Investigator Grade Assessment (IGA) from baseline</measure>
    <time_frame>Week 28</time_frame>
    <description>Subjects achieving a 1 point reduction from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Body Surface Area (BSA) from baseline</measure>
    <time_frame>Week 28</time_frame>
    <description>Subjects achieving a 50% reduction from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Complete Metabolic Profile Values From Baseline Due to the Combination of Topical Triamcinolone Cream and Oral Vitamin D3</measure>
    <time_frame>Week 28</time_frame>
    <description>Assess change through complete metabolic profile laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parathyroid Hormone Level Values From Baseline Due to the Combination of Topical Triamcinolone Cream and Oral Vitamin D3</measure>
    <time_frame>Week 28</time_frame>
    <description>Assess change through parathyroid hormone level laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 25-Hydroxyvitamin D Values From Baseline Due to the Combination of Topical Triamcinolone Cream and Oral Vitamin D3</measure>
    <time_frame>Week 28</time_frame>
    <description>Assess change through 25-Hydroxyvitamin D laboratory values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Plaque Psoriasis</condition>
  <condition>Vitamin D3</condition>
  <arm_group>
    <arm_group_label>Triamcinolone Cream + Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will continue to take Vitamin D3 at Week 16 to Week 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Cream + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Triamcinolone 0.1% daily</description>
    <arm_group_label>Triamcinolone Cream + Placebo</arm_group_label>
    <arm_group_label>Triamcinolone Cream + Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>40,000 IU Vitamin D3 daily</description>
    <arm_group_label>Triamcinolone Cream + Placebo</arm_group_label>
    <arm_group_label>Triamcinolone Cream + Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily</description>
    <arm_group_label>Triamcinolone Cream + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and older

          -  Mild to severe plaque psoriasis (2% or greater Body Surface Area; Psoriasis Area and
             Severity Score of 2 or greater; Investigator Grade Assessment of mild-severe)

        Exclusion Criteria:

          -  Currently taking medication that alters the normal ion balance of low-dose in blood.

          -  No calcium supplements 1 month prior to baseline (not including multivitamins).

          -  Unstable or uncontrolled illness, including but not limited to cerebro-cardiovascular,
             respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or
             psychiatric disease at screening.

          -  Abnormal laboratory values at screening, that in the opinion of the investigator,
             would potentially affect patient safety or data integrity.

          -  Not on systemic non-biologic therapy (including, but not limited to, oral psoralen
             plus ultraviolet A [PUVA] light therapy; cyclosporine; corticosteroids; methotrexate;
             oral retinoids; apremilast; tofacitinib; mycophenolate mofetil; thioguanine;
             hydroxyurea; sirolimus; tacrolimus; azathioprine; lefludimide; fumaric acid
             derivatives; or 1, 25 dihydroxy vitamin D3 and analogues) within 28 days prior to
             baseline.

          -  No phototherapy (including either oral and topical PUVA light therapy, ultraviolet B,
             excimer laser, or self-treatment with tanning beds or therapeutic sunbathing) within
             28 days prior to baseline.

          -  No topical treatment (including, but not limited to, corticosteroids [upper mid
             strength or lower potency topical steroids are permitted on the intertriginous areas
             and face], crisaborole, anthralin, calcipotriene, topical vitamin D derivatives,
             retinoids, tazarotene, pimecrolimus, tacrolimus, emollients and other nonprescription
             topical products containing urea, &gt;3% salicylic acid, alpha- or beta-hydroxyl acids,
             or medicated shampoos [for example those that contain &gt;3% salicylic acid,
             corticosteroids, coal tar, or vitamin D3 analogues]) within 14 days prior to baseline.

          -  No biologic agents within 8 weeks or three half-lives, whichever is greater prior to
             baseline.

          -  History of renal impairment.

          -  History of renal stones.

          -  History of parathyroid abnormalities

          -  Osteoporosis

          -  History of severe arthritis

          -  Ongoing use of tanning bed or other UV device or excessive sunlight

          -  Unable to understand/complete informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Travers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State Physicians</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager, Clinical Research Operations</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regulatory Specialist</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wright State Physicians</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Travers, MD, PhD</investigator_full_name>
    <investigator_title>Chair, Department of Pharmacology and Toxicology for Boonshoft School of Medicine, Wright State Physicians</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

